Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 7/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3702492 | 0.86 | PTPN11 (0.36) | SORDSMN1; SMN2PTPN11 | |
| SCHEMBL3711697 | 0.86 | STK4 (0.36) | SORDSMN1; SMN2PTPN11ALDH1A1 | |
| SCHEMBL3702797 | 0.80 | — | — | |
| SCHEMBL3784401 | 0.78 | SCD (0.30) | — | |
| SCHEMBL1709870 | 0.78 | PDE10A (0.39) | — | |
| SCHEMBL3716880 | 0.77 | CYP11B2 (0.36) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL189922 | 0.76 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL3707912 | 0.76 | CYP1A2 (0.38) | — | |
| SCHEMBL3711359 | 0.76 | PIK3CA (0.37) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL1709781 | 0.75 | NCF1 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | SORD 645/4885SMN1; SMN2 4293/4885PTPN11 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.